Key facts
- It has raised $790K; the latest was Seed Round ($740K) in Jun 2025.
- Notable investors include Alpha Stage, AmCham EU, Bank of Cyprus Group, Cyprus Seeds, EGG Enter Grow Go — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for MammoCheck
- ·The full record, as it builds
Funding rounds
No funding rounds for MammoCheck are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MammoCheck
Developer of home-based health screening systems designed for early detection of breast abnormalities. The company offers an at-home screening kit with straightforward instructions, quick result turnaround, non-invasive sample collection, and digital result delivery through a secure interface, enabling women to regularly monitor their breast health, identify abnormalities early, and make informed decisions about seeking clinical follow-up without visiting a healthcare facility.
- Sector
- Healthcare
- HQ
- Nicosia, Cyprus
- Founded
- 2021
- Employees
- 5
- Website
- mammocheck.co/
- Ownership
- Privately Held (backing)
MammoCheck doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MammoCheck shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MammoCheck in its N-PORT filings yet. We sweep new filings monthly.